01 August 2005
The use of recombinant human activated protein C (rhAPC) in the treatment of severe sepsis in immunosuppressed patients in the course of hematological diseases.
Anna Kunsdorf-Wnuk, Ewa Marzec-Lewenstein, Danuta Arct-Danielak, Ewa Musioł, Romuald Bohatyrewicz, Rafał BechtMed Sci Monit 2005; 11(8): CS49-55 :: ID: 202172
Abstract
Background: Treatment of hemopoietic system neoplasias involves severecomplications associated with immunosuppression. We present two cases of treating severe sepsis utilizingrecombinant human activated protein C (rhAPC) in the course of bilateral pneumonia in patients with hairycell leukemia (HCL) and T-cell acute lymphoblastic leukemia (ALL). RhAPC, limited the coagulation cascadeby inactivating FVa and FVIIIa, directly and indirectly limiting systemic inflammatory response syndrome(SIRS), and improved the fibrinolysis process. These actions break the pathomechanism of sepsis and improvesurvival. Case Report: Besides intensive, multidirectional treatment of severe sepsis, Xigris (activateddrotrecogin alfa) was administered on the second day in both cases. The infusion continued, as recommended,for 96 hours without complications. During treatment the patients' general condition and respiratoryefficiency improved, allowing respirator weaning on days 5 and 8 of therapy. These cases of severe sepsisand immunosuppression indicate a high therapeutic efficacy of drotrecogin alfa (activated). Treatmentoutcome was uncertain because of the patients' hematological condition, so rapid restoration of respiratoryefficiency and no disease progression after discontinuing treatment was a great success, possibly dueto implementing Xigris at a relatively early stage of sepsis and the intensive therapy conducted accordingto Surviving Sepsis Campaign guidelines. Conclusions: Patient survival in severe sepsis directly dependson early diagnosis and institution of treatment. 1. These cases confirm the effectiveness of drotrecoginalfa in severe sepsis as part of multidirectional therapy. 2. Microorganisms causing atypical pneumoniashould be considered in diagnosing infections in patients treated with cytostatic agents.
Keywords: Leukemia, Lymphocytic, Acute - complications, Immune Tolerance, Leukemia, Hairy Cell - therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy, Protein C - therapeutic use, Recombinant Proteins - therapeutic use, Sepsis - drug therapy
Editorial
01 April 2024 : Editorial
Editorial: Forty Years of Waiting for Prevention and Cure of HIV Infection – Ongoing Challenges and Hopes for Vaccine Development and Overcoming Antiretroviral Drug ResistanceDOI: 10.12659/MSM.944600
Med Sci Monit 2024; 30:e944600
In Press
07 Mar 2024 : Clinical Research
Knowledge of and Attitudes Toward Clinical Trials: A Questionnaire-Based Study of 179 Male Third- and Fourt...Med Sci Monit In Press; DOI: 10.12659/MSM.943468
08 Mar 2024 : Animal Research
Modification of Experimental Model of Necrotizing Enterocolitis (NEC) in Rat Pups by Single Exposure to Hyp...Med Sci Monit In Press; DOI: 10.12659/MSM.943443
18 Apr 2024 : Clinical Research
Comparative Analysis of Open and Closed Sphincterotomy for the Treatment of Chronic Anal Fissure: Safety an...Med Sci Monit In Press; DOI: 10.12659/MSM.944127
08 Mar 2024 : Laboratory Research
Evaluation of Retentive Strength of 50 Endodontically-Treated Single-Rooted Mandibular Second Premolars Res...Med Sci Monit In Press; DOI: 10.12659/MSM.944110
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952